Skip to main content

Smith & Nephew Snats ADR(SNN-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low33.01
Day High33.67
Open:33.34
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

Top Stories: Smith & Nephew Snats ADR

Select a category then submit the form to load news
GlobeNewswire
Smith+Nephew launches next-generation ALLEVYN™ COMPLETE CARE Foam Dressing - designed for high performance in wound management and pressure injury prevention
Tipranks
Smith+Nephew CEO Deepak Nath to Join Reckitt Board as Independent Director
Tipranks
Smith & Nephew (SN) Receives a Buy from Goldman Sachs
Tipranks
Kepler Capital Remains a Buy on Smith & Nephew (SN)
Tipranks
Barclays Reaffirms Their Hold Rating on Smith & Nephew (SN)
Tipranks
Smith & Nephew Earnings Call Highlights Profitable Momentum
Tipranks
Smith & Nephew Updates Voting Share Capital and Rights as of 28 February 2026
Tipranks
Smith+Nephew Posts Strong 2025 Results, Completes Transformation and Sets 2026 Growth Targets
Tipranks
Smith & Nephew Posts Strong 2025 Results and Unveils Next-Phase Growth Strategy
GlobeNewswire
Smith+Nephew to feature leading rotator cuff repair portfolio including new Tendon Seam™ Repair System and REGENETEN◊ Bioinductive Implant at AAOS 2026
Tipranks
Smith & Nephew announces U.S. distribution agreement with RMR Ortho
Tipranks
Barclays Remains a Hold on Smith & Nephew (SN)
Tipranks
Smith+Nephew Sets 2 March 2026 Date for 2025 Full-Year Results
Tipranks
Smith & Nephew Reports Routine Six-Month Update on Employee Share Schemes
Tipranks
Smith & Nephew Updates Share Capital and Voting Rights as of 31 January 2026
Tipranks
Smith & Nephew Executives Buy ADS under Employee Stock Purchase Plan
Tipranks
Smith & Nephew Snats (SNN) Gets a Hold from Berenberg Bank
Tipranks
Smith & Nephew (SN) Receives a Hold from Barclays
Tipranks
Smith+Nephew Closes US$450m Integrity Orthopaedics Deal to Bolster Sports Medicine Portfolio
GlobeNewswire
Smith+Nephew completes acquisition of Integrity Orthopaedics; establishes unrivalled portfolio for shoulder repair
Zacks Investment Research
SNN Boosts Shoulder Repair Portfolio With Integrity Orthopaedics Deal
SNN Boosts Shoulder Repair Portfolio With Integrity Orthopaedics Deal
Tipranks
Canaccord Genuity Sticks to Its Hold Rating for Smith & Nephew Snats (SNN)
Tipranks
Smith+Nephew to Acquire Integrity Orthopaedics to Bolster Shoulder Repair Portfolio
Tipranks
Smith & Nephew’s PICO Venous Leg Ulcer Study Terminated: What Investors Should Know
Tipranks
Smith & Nephew Updates Share Capital and Voting Rights as of Year-End 2025
Tipranks
Canaccord Genuity Reaffirms Their Hold Rating on Smith & Nephew Snats (SNN)
Tipranks
Smith & Nephew (SN) Receives a Buy from Citi
Tipranks
Kepler Capital Sticks to Their Buy Rating for Smith & Nephew (SN)
Tipranks
Goldman Sachs Sticks to Its Buy Rating for Smith & Nephew (SN)
Tipranks
Barclays Sticks to Their Hold Rating for Smith & Nephew (SN)
Tipranks
Smith & Nephew Snats Updates Share Capital Structure
Tipranks
Barclays Sticks to Its Hold Rating for Smith & Nephew (SN)

Profile

Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physicianadvantage and real patient benefits. A continuous process of supplying new and innovative products is supported by substantial R&D investment todeliver new levels of healing to patients throughout the world

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.